ClinicalTrials.gg
Active, not recruitingNCT07368959Updated Sep 24, 2026

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

A Phase 3 interventional study of Combination Product: AURN001 + Y-27632 and Placebo in Corneal Edema, Corneal Endothelial Dysfunction and Fuchs Endothelial Corneal Dysfunction, sponsored by Aurion Biotech. Active, not recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Aurion Biotech · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Corneal Edema with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Corneal Edema · United States.

Enrollment
3rd of 14
130 · median 61
Started
2026
with 1 other
Phase 3
2 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
2 of 17
Aurion Biotech

Among the 17 studies in Corneal Edema with a site in United States, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 3, and was the 16th registered.

Corneal Edema

39 studies on the registry are indexed under Corneal Edema; 8 are open to participants now.

Browse Corneal Edema studies →

Open to participants now

2 of the 17 studies in Corneal Edema with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Corneal Edema studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Corneal Edema with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.

03

Conditions studied

  • Corneal Edema
  • Corneal Endothelial Dysfunction
  • Fuchs Endothelial Corneal Dysfunction
  • Pseudophakic Bullous Keratopathy (PBK)

Browse trials for

Keywords

  • Best Corrected Visual Acuity
  • Central corneal thickness
  • Human Corneal Endothelial Cells
  • Neltependocel
  • Postsurgical endothelial dysfunction
  • Keratoplasty
  • Pseudophakic Corneal Edema (PCE)
  • Corneal Endothelial Cells
  • Endothelial Cells
  • AURN001
  • Y-27632
  • Endothelial Keratoplasty
  • Corneal Endothelial Cell Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Ocular Inclusion Criteria:

(All ocular criteria apply to the study eye unless noted otherwise)

  • Have corneal edema secondary to corneal endothelial dysfunction, requiring surgery (full- or partial-thickness endothelial keratoplasty)
  • BCVA between 65 ETDRS letters (approximate 20/50 Snellen equivalent) and 5 ETDRS letters (approximate 20/800 Snellen equivalent)
  • Be pseudophakic with PCIOL

Key Ocular Exclusion Criteria:

(All ocular criteria apply to the study eye unless noted otherwise)

  • Have progressive corneal dystrophies or degenerations
  • Have visually significant corneal or other ocular pathologies

Other inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    AURN001

    Participants will receive single dose of AURN001

    Drug: Combination Product: AURN001 + Y-27632

  • Placebo comparator
    Placebo

    Participants will receive single dose of placebo control.

    Other: Placebo

Interventions

  • DrugCombination Product: AURN001 + Y-27632

    AURN001 will be injected to the anterior chamber of the eye.

  • OtherPlacebo

    Placebo control will be injected to the anterior chamber of the eye.

06

What researchers measure

Primary outcomes

  1. Percentage of participants who achieve a ≥ 15-letter improvement (3-line gain) from baseline in Best Corrected Visual Acuity (BCVA) at Month 6

    Time frame: At Month 6

Secondary outcomes

  1. Change from baseline in non-contact Central Corneal Thickness (CCT) at Month 6

    Time frame: Baseline (Day 1) and At Month 6

  2. Change from baseline in BCVA at Month 6

    Time frame: Baseline (Day 1) and At Month 6

07

Study locations

12 sites
  • Investigational Site 2
    Mesa, Arizona 85206, United States
  • Investigational Site 6
    Little Rock, Arkansas 72205, United States
  • Investigational Site 9
    Fort Collins, Colorado 80528, United States
  • Investigational Site 7
    Atlanta, Georgia 30339, United States
  • Investigational Site 4
    Kansas City, Missouri 64154, United States
  • Investigational Site 11
    Leland, North Carolina 28451, United States
  • Investigational Site 5
    Winston-Salem, North Carolina 27157, United States
  • Investigational Site 3
    Cynwyd, Pennsylvania 19004, United States
  • Investigational Site 10
    Plymouth Meeting, Pennsylvania 19462, United States
  • Investigational Site 12
    Ladson, South Carolina 29456, United States
  • Investigational Site 8
    San Antonio, Texas 78209, United States
  • Investigational Site 1
    Spring, Texas 77388, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 27, 2026
StartActual
Feb 19, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jan 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07368959
Lead sponsor
Aurion Biotech
Responsible party
Sponsor
First posted
Jan 27, 2026
Start date
Feb 19, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Sep 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion